DOCSLIB.ORG

Dermatologic Manifestations of Giardiasis J Am Board Fam Pract: First Published As 10.3122/Jabfm.5.4.425 on 1 July 1992

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dermatologic Manifestations of Giardiasis J Am Board Fam Pract: First Published As 10.3122/Jabfm.5.4.425 on 1 July 1992 Dermatologic Manifestations Of Giardiasis J Am Board Fam Pract: first published as 10.3122/jabfm.5.4.425 on 1 July 1992. Downloaded from jerry T. McKnight, M.D., and Paul E. Tietze, M.D. Giardia lamblia is the most common intestinal The physical examination was remarkable only parasite in the United States and is worldwide in for an eczematous-type dermatitis with erythema, distribution.l Approximately 4 percent of stool xerosis, and several fine papular and vesicular specimens submitted to public health laboratories lesions on the extremities. The rash was con­ in this country contain Giardia cysts.2 The usual fined primarily to the trunk and extremities symptoms of acute giardiasis include diarrhea, and was located predominately on the flexor sur­ abdominal cramps, nausea, and weight loss. faces. This pattern was consistent with the previ­ Many, if not most, individuals with Giardia infec­ ous diagnosis of atopic dermatitis. The involved tion are asymptomatic. Giardiasis can be an acute skin was excoriated, and lichenification was self-limiting diarrheal illness, or it can lead to present. chronic diarrhea and malabsorption.3 Children The patient's complete blood count, chemical are affected more often than adults, and person­ analysis of serum, urinalysis, and thyroid profile to-person transmission has been documented.4,s were normal. The serum immunoglobin E(IgE) There have been reports of allergic symptoms was 48 ,....glL (20 U/mL), normal 24-240 ,....glL associated with giardiasis. This article describes a (10-100 U/mL). case of dermatitis associated with Giardia infec­ The medications were changed to fluocinonide tion and reviews dermatologic manifestations of ointment 0.05 percent twice daily and terfenadine Giardia lamblia infection. 60 mg twice daily. This medication regimen de­ creased symptoms somewhat; however, the der­ Case Report matitis persisted with the pruritus being especially A 48-year-old woman complained of an 8-month bothersome. history of atopic dermatitis. The patient had Several weeks after changing medications, the been cared for by a dermatologist, who pre­ patient developed the new complaint of abdomi­ scribed triamcinolone ointment 0.1 percent topi­ nal cramping without nausea, diarrhea, or weight cally twice daily, hydroxyzine hydrochloride 25 loss. Further questioning revealed that cramp­ mg four times daily, and doxepin hydrochloride ing had been an intermittent problem start­ http://www.jabfm.org/ 50 mg at bedtime. This treatment provided some ing soon after coming to live with her daughter. symptomatic relief but had not cleared the mark­ A stool culture was negative for enteric patho­ edly pruritic chronic dermatitis. There was no gens; however, a microscopic examination history of atopy, nor was there any history of showed numerous Giardia cysts. Treatment with dermatologic conditions. The patient requested metronidazole, 250 mg three times a day for her medications be changed because of worsen­ 7 days, relieved the abdominal complaints. Addi­ on 25 September 2021 by guest. Protected copyright. ing of the rash. tionally, the dermatitis completely resolved The patient's medical history was unremark­ within 2 weeks. All medications were discon­ able except one previous hospitalization for an tinued, and the rash had not recurred after 18 uncomplicated childbirth. The social history was months of follow-up care. pertinent for a move to east Tennessee 10 months The suspected source of infection was an earlier from her native country of Germany to underground well, which was the only water live with her daughter. The dermatitis developed source for the family. The local health de­ approximately 2 months after moving. partment believed it was impractical to filter mass quantities of water for detection of Giardia. The other family members were asked to have Submitted, revised, 2 October 1991. stool specimens for parasites. No members of From the Department of Family Medicine, University of the household were symptomatic, and they de­ . Alabama, Tuscaloosa. Address reprint requests to Jerry T. McKnight, M.D., Department of Family Medicine, University clined. The family was asked to boil water used of Alabama, 107 Educational Tower, Tuscaloosa, AL 35401. for consumption. Dermatologic Manifestations of Giardiasis 425 i! i) ,. Discussion ritus, and anal itching. Urticaria or dermatitis was J Am Board Fam Pract: first published as 10.3122/jabfm.5.4.425 on 1 July 1992. Downloaded from This case illustrates a possible complication of not specifically reported. The report indicated giardiasis. An extensive review of the medical lit­ that after treatment with either metronidawle or erature, including foreign sources, revealed sev­ quinacrine, 90 percent of the articular and extra­ eral references to dermatologic manifestations, articular signs and symptoms disappeared.II specifically urticaria, associated with giardiasis.6-s Another specific report of note is that by Infection with Giardia has been associated with Chirila, et al.,IO who in 1981 studied 434 patients urticaria, pruritus, and possibly angioedema.9,10 who came to the Department of Allergy at the Other allergic manifestations, such as reactive ar­ Institute of Internal Medicine in Bucharest. Of thritis, have also been reported.ll Giardia is not these patients, 186 had chronic urticaria, 120 had usually associated with elevated IgE levels or angioedema, and 50 had both urticaria and an­ eosinophilia.S,12 Appropriate treatment of this gioedema. Giardia was found in 74 (40 percent) of parasite resulted in complete resolution of patients with chronic urticaria, in 42 (35 percent) .,1 skin manifestations in all cases described. The of patients with angioedema, and in 48 (96 per­ cases described in the literature are presented cent) of patients who had both chronic urticaria . I in Table 1. and angioedema. The authors indicated clinical Additional studies not tabulated include a study symptoms were rarely suggestive of giardiasis. in 1977 of 66 Argentinian children, aged 2 to 15 Giardia was found in these allergic patients three years, who came to a rheumatology clinic with times more frequently than the normal popula­ joint symptoms. Goobarll reported that these tion of Rumania. The authors did not report der­ , ! children had joint symptoms of pain accompanied matologic response to treatment in these patients. by synovitis. Sixty-four of these children had There have been many cases of urticaria associ­ I, I giardiasis. The 66 patients were selected because ated with Giardia lamblia infection. Previous ap­ of gastrointestinal symptoms, including diarrhea, proximations of nine total cases by Hamrick and nausea or vomiting, abdominal cramps, or bloody Moorel9 in 1983 and 20 cases by Clyne and stools. Sixty percent had what were described as Eliopoulos20 in 1989 were underestimations. The allergic symptoms: nasal itching, generalized pru- total number of cases reported is 33, not counting Table 1. Literature Rmew of GianUasis AII80dated wi1Il U1tlcarla or Prurltis. , , ; http://www.jabfm.org/ ~ Year Cases Ages (yr) Other Symptoms Treaonent Outcome 1949 1 16 Diarrhea, abdominal pain Quinacrine All symptoms resolved6 , 1, 1957 2 34,42 Diarrhea, weight loss Quinacrine All symptoms resolved7 1958 6* NR Gastrointestinal symptoms Quinacrine Urticaria resolved8 1969 St NR NR NR NR13 1976 1 28 Diarrhea, weight loss Metronidazole All symptoms resolved 14 on 25 September 2021 by guest. Protected copyright. 1978 4 NR Diarrhea Metronidazole All symptoms resolved 15 1979 30s None Metronidazole Urticaria resolved16 1980 3 1,13.35 Anorexia. diarrhea. weight loss Metronidazole All symptoms resolved17 1983 6* 5-33 50% had gastrointestinal symptoms Metronidazole All symptoms resolved 18 1983 4 None Metronidazole All S}'D}ptoms resolved 19 1983 6 Diarrhea, arthritis Metronidazole All symptoms resolved9 1989 28 Diarrhea, fever Metronidazole All symptoms resolved2o 1989 1 53 Diarrhea. fever Metronidazole Uticaria resolved21 1990 IS NR Mild gastrointestinal symptoms Metronidazole All symptoms resolved22 NR • not reported. *6 of 32 patients with giardiasis. tS of 500 patients with giardiasis. *6 of 50 patients with chronic urticaria. §Self-report, allergist, pruritis only. 426 JABFP July-August 1992 Vol. 5 No.4 additional cases unreported by Kennou, et alP the association with Giardia is immunologically J Am Board Fam Pract: first published as 10.3122/jabfm.5.4.425 on 1 July 1992. Downloaded from and the Rumanian study,IO which did not re­ based. This reaction, however, might not be a port response to treatment. Goobarll also did classical IgE-mediated phenomenon.33 Although not quantitate the exact number with pruritus urticaria is not a usual manifestation of Giardia, it or the specific response to treatment in each should be recognized, especially in view of the incident. ubiquitous nature of the organism. Because Some of these patients had few if any gastroin­ chronic urticaria is a relatively common dermato­ testinal symptoms. This finding is not surprising logic disorder and results in a frequently frustrat­ in view of the known history of giardiasis.3 The ing and unfruitful evaluation, it would be reason­ types of gastrointestinal presentations of giardia­ able to include Giardia in the differential sis range from minimal or no symptoms to diar­ diagnosis and to search for Giardia by either mi­ rhea and weight loss. 3 Fever is also occasionally croscopic stool analysis or by the newer and per­ seen.20,23,24 The number of reports and the differ­ haps more
Load more

Recommended publications
  • Giardiasis Importance Giardiasis, a Gastrointestinal Disease Characterized by Acute Or Chronic Diarrhea, Is Caused by Protozoan Parasites in the Genus Giardia
    Giardiasis Importance Giardiasis, a gastrointestinal disease characterized by acute or chronic diarrhea, is caused by protozoan parasites in the genus Giardia. Giardia duodenalis is the major Giardia Enteritis, species found in mammals, and the only species known to cause illness in humans. This Lambliasis, organism is carried in the intestinal tract of many animals and people, with clinical signs Beaver Fever developing in some individuals, but many others remaining asymptomatic. In addition to diarrhea, the presence of G. duodenalis can result in malabsorption; some studies have implicated this organism in decreased growth in some infected children and Last Updated: December 2012 possibly decreased productivity in young livestock. Outbreaks are occasionally reported in people, as the result of mass exposure to contaminated water or food, or direct contact with infected individuals (e.g., in child care centers). People are considered to be the most important reservoir hosts for human giardiasis. The predominant genetic types of G. duodenalis usually differ in humans and domesticated animals (livestock and pets), and zoonotic transmission is currently thought to be of minor significance in causing human illness. Nevertheless, there is evidence that certain isolates may sometimes be shared, and some genetic types of G. duodenalis (assemblages A and B) should be considered potentially zoonotic. Etiology The protozoan genus Giardia (Family Giardiidae, order Giardiida) contains at least six species that infect animals and/or humans. In most mammals, giardiasis is caused by Giardia duodenalis, which is also called G. intestinalis. Both names are in current use, although the validity of the name G. intestinalis depends on the interpretation of the International Code of Zoological Nomenclature.
    [Show full text]
  • Drugs for Amebiais, Giardiasis, Trichomoniasis & Leishmaniasis
    Antiprotozoal drugs Drugs for amebiasis, giardiasis, trichomoniasis & leishmaniasis Edited by: H. Mirkhani, Pharm D, Ph D Dept. Pharmacology Shiraz University of Medical Sciences Contents Amebiasis, giardiasis and trichomoniasis ........................................................................................................... 2 Metronidazole ..................................................................................................................................................... 2 Iodoquinol ........................................................................................................................................................... 2 Paromomycin ...................................................................................................................................................... 3 Mechanism of Action ...................................................................................................................................... 3 Antimicrobial effects; therapeutics uses ......................................................................................................... 3 Leishmaniasis ...................................................................................................................................................... 4 Antimonial agents ............................................................................................................................................... 5 Mechanism of action and drug resistance ......................................................................................................
    [Show full text]
  • Dientamoeba Fragilis – the Most Common Intestinal Protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Helsingin yliopiston digitaalinen arkisto Research Dientamoeba fragilis – the most common intestinal protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017 Jukka-Pekka Pietilä1, Taru Meri2, Heli Siikamäki1, Elisabet Tyyni3, Anne-Marie Kerttula3, Laura Pakarinen1, T Sakari Jokiranta4,5, Anu Kantele1,6 1. Inflammation Center, Infectious Diseases, Helsinki University Hospital and Helsinki University, Helsinki, Finland 2. Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland 3. Division of Clinical Microbiology, Helsinki University Hospital, HUSLAB, Helsinki, Finland 4. Medicum, University of Helsinki, Finland 5. SYNLAB Finland, Helsinki, Finland 6. Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Finland Correspondence: Anu Kantele ([email protected]) Citation style for this article: Pietilä Jukka-Pekka, Meri Taru, Siikamäki Heli, Tyyni Elisabet, Kerttula Anne-Marie, Pakarinen Laura, Jokiranta T Sakari, Kantele Anu. Dientamoeba fragilis – the most common intestinal protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017. Euro Surveill. 2019;24(29):pii=1800546. https://doi.org/10.2807/1560- 7917.ES.2019.24.29.1800546 Article submitted on 08 Oct 2018 / accepted on 12 Apr 2019 / published on 18 Jul 2019 Background: Despite the global distribution of of Dientamoeba-like structures in formalin-fixed sam- the intestinal protozoan Dientamoeba fragilis, its ples, an approach applicable also in resource-poor clinical picture remains unclear. This results from settings. Symptoms of dientamoebiasis differ slightly underdiagnosis: microscopic screening methods from those of giardiasis; patients with distressing either lack sensitivity (wet preparation) or fail to symptoms require treatment.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 MICROBIOLOGY / VIROLOGY REVIEW(S) Division of Anti-Infective Products Clinical Microbiology Review NDA 204684 (Original NDA) Page 2 of 129 PROPOSED DOSAGE FORM AND STRENGTH: Capsules, each containing 50 mg miltefosine. ROUTE OF ADMINISTRATION AND DURATION OF TREATMENT: Impavido is recommended to be taken orally daily for 28 days with food. The number of 50 mg capsules per day will be determined by bodyweight: • 30–44 kg (66–97 lbs): one 50 mg capsule twice daily with food. • ≥45 kg (99 lbs): one 50 mg capsule three times daily with food. DISPENSED: Rx RELATED DOCUMENTS: IND 105,430 REMARKS The subject of this NDA is miltefosine for the treatment of visceral, mucosal, and cutaneous leishmaniasis. The nonclinical and clinical microbiology studies, submitted by the applicant or obtained by an independent literature search, support the activity of miltefosine against visceral, mucosal, and cutaneous leishmaniasis. A potential for development of resistance to miltefosine exists and may be due increase in drug efflux, mediated by the overexpression of the ABC transporter P-glycoprotein and/or a decrease in drug uptake by the inactivation of the miltefosine transport machinery that consists of the miltefosine transporter and its beta subunit. Mutation in the transporter gene was reported in a relapsed patient in one study. Also, some strains of L. braziliensis with intrinsic resistance to miltefosine have been identified. Such information should be included in ‘Microbiology’ subsection of the labeling. In clinical studies, the parasitological measurements at the time of screening included direct examination of aspirates/smears; at the end of treatment or follow-up visits parasitological measurements were made if clinically indicated.
    [Show full text]
  • Giardiasis Public Information
    Louisiana Office of Public Health Infectious Disease Epidemiology Section Phone: 1-800-256-2748 www.infectiousdisease.dhh.louisiana.gov Information on Giardiasis Public Information What is the treatment for giardiasis? What is giardiasis? Several prescription drugs are available to treat Giardia; you Giardiasis (GEE-are-DYE-uh-sis) is a diarrheal illness caused by should consult with your health care provider. Young children a very small parasite, Giardia intestinalis (also known as Giar- and pregnant women may be more likely to get dehydrated dia lamblia). Once an animal or person is infected with Giar- from diarrhea, and should drink plenty of fluids while ill. In dia, the parasite lives in the intestine and is passed in the some cases, symptoms of giardiasis will go away without any stool. The parasite is protected by an outer shell and can sur- treatment. vive outside the body and in the environment for a long time. Giardia and drinking water In the past two decades, Giardia infection has become one of the most common causes of waterborne disease (found in both Where and how does Giardia get into drinking water? drinking and recreational water) in humans in the U.S.. Giar- dia infections are more common in warmer climates, though Millions of Giardia parasites can be released in a bowel move- they may be found worldwide and in every region of the US. ment of an infected human or animal. Feces from these hu- mans or animals can get into your well through different ways How do I become infected with giardia? including sewage overflows, polluted storm water runoff, and agricultural runoff.
    [Show full text]
  • Brain-Eating Ameba Pdf Icon[PDF – 31 Pages]
    CDC Science Ambassador Workshop 2013 Lesson Plan Brain-Eating Ameba Developed by Jewel B. Moses, PhD Arcot M. Saibaba, PhD Southeast Middle School Newton High School Hopkins, South Carolina Covington, Georgia This lesson plan was developed by teachers attending the Science Ambassador Workshop. The Science Ambassador Workshop is a career workforce training for math and science teachers. The workshop is a Career Paths to Public Health activity in the Division of Scientific Education and Professional Development, Center for Surveillance, Epidemiology, and Laboratory Services, Office of Public Health Scientific Services, Centers for Disease Control and Prevention. Acknowledgements This lesson plan was developed in consultation with subject matter experts from the Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention. Jennifer Cope, MD, MPH Jonathan Yoder, MSW, MPH Medical Epidemiologist Epidemiologist Scientific and editorial review was provided by Ralph Cordell, PhD and Kelly Cordeira, MPH from Career Paths to Public Health, Division of Scientific Education and Professional Development, Center for Surveillance, Epidemiology, and Laboratory Services, Office of Public Health Scientific Services, Centers for Disease Control and Prevention. Suggested citation Centers for Disease Control and Prevention (CDC). Science Ambassador Workshop—Brain-eating Ameba. Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/scienceambassador/lesson-plans/index.html. Contact Information Please send questions and comments to [email protected]. Disclaimers This lesson plan is in the public domain and may be used without restriction. Citation as to source, however, is appreciated. Links to nonfederal organizations are provided solely as a service to our users.
    [Show full text]
  • LUMC Course Parasitology ESCMID Online Lecture Library © by Author
    Giardia lamblia and Dientamoeba fragilis clinical aspects, diagnostics and epidemiology © Theoby Mankauthor ESCMID Online Lecture Library LUMC course parasitology Dientamoeba © by author ESCMID Online Lecture Library LUMC course parasitology Giardia lamblia the parasite that keeps surprising © by author ESCMID Online Lecture Library LUMC course parasitology Giardia lamblia • 1681: Giardia was first observed by Anthony van Leeuwenhoek, the pioneering microscopist from Delft, The Netherlands, in his watery stools • Late 70s: Giardia was recognized as a human pathogen, based on symptoms such as malabsorption and the pathology observed in the upper part of the small intestine in patients from whom the organism was isolated (Koulda and Nohynova 1978) • 1981: The World Health© Organization by author added Giardia to its list of parasitic pathogens • ESCMID2006: Giardia was Online added to the LectureWHO “Neglected Library Disease Initiative” (Savioli et al, 2006) LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology © by author ESCMID Online Lecture Library LUMC course parasitology Prevalence • Cosmopolitan • Depending on the population – Higher in case of suboptimal sanitation – Quality of drinking water – Developing countries© by author ESCMID–
    [Show full text]
  • Giardia and Animals
    Giardia and Animals What is giardiasis? Giardiasis is caused by infection of the small intestine by a tiny parasite (protozoan) called Giardia intestinalis (also known as G. lamblia and G. duodenalis). Giardiasis is a problem all over the world, particularly in resource-poor countries. In the United States, Giardia infection is the most common intestinal parasitic disease affecting humans. In Washington State, 400-600 Giardia cases are reported annually, including 100-150 cases from King County. In addition, there are many Giardia infections that are never diagnosed and reported. What are the symptoms of Giardia infection? Infected people may have no symptoms, or they may have mild to severe symptoms including watery foul-smelling diarrhea, stomach cramps, gas, fever, nausea, vomiting, and headache. Symptoms start 1 to 3 weeks after a person has become infected and they may be more severe in people who are immune compromised. Giardia infection can be diagnosed by examining a stool sample. Because Giardia cysts can be shed off and on they can be hard to find and it may be necessary to check several stool samples. How is Giardia infection treated? Giardiasis often clears up without treatment. People with symptoms can be treated with prescription medications such as Quinacrine hydrochloride, Metronidazole, or Furazolidone. How is Giardia spread? People can become infected with Giardia by swallowing Giardia cysts found in contaminated water or food. Giardia may also be passed by direct contact with feces from an infected person or animal. Fecal- oral spread can occur in child-care settings, households and during oral-anal sexual contact.
    [Show full text]
  • IDCM Section 3: Giardiasis
    GIARDIASIS REPORTING INFORMATION • Class B: Report by the close of the next business day in which the case or suspected case presents and/or a positive laboratory result to the local public health department where the patient resides. If patient residence is unknown, report to the local public health department in which the reporting health care provider or laboratory is located. • Reporting Form(s) and/or Mechanism: o The Ohio Disease Reporting System (ODRS) should be used to report lab findings to the Ohio Department of Health (ODH). For healthcare providers without access to ODRS, you may use the Ohio Confidential Reportable Disease form (HEA 3334). o The Ohio Enteric Case Investigation Form will be useful in the local health department follow-up of cases. Do not send this form to the Ohio Department of Health (ODH); information collected from the form should be entered into ODRS where all fields are available and the form should be uploaded in the Administration section of ODRS. • Key Fields for ODRS reporting include: sensitive occupation or attendee of daycare, symptoms of and number ill in the household, travel and water exposure. CASE DEFINITION Clinical Case Definition An illness caused by the protozoan Giardia lamblia (also known as G. intestinalis or G. duodenalis) and characterized by gastrointestinal symptoms such as diarrhea, abdominal cramps, bloating, weight loss, or malabsorption. Laboratory Criteria for Diagnosis Laboratory-confirmed giardiasis shall be defined as the detection of Giardia organisms, antigen, or DNA in stool, intestinal fluid, tissue samples, biopsy specimens, or other biological sample. Case Classification Suspect*: A clinically compatible case with presumptive or pending lab results and is not epidemiologically linked to a confirmed case.
    [Show full text]
  • GIARDIASIS [Most Common Intestinal Protozoan Parasite of People in the U.S.]
    GIARDIASIS [Most common intestinal protozoan parasite of people in the U.S.] SPECIES: dogs, cats, NHP, most likely AGENT: Giardia lamblia Has both a cyst (infective) and trophozoite form RESERVOIR AND INCIDENCE: The parasite occurs worldwide and is nearly universal in children in developing countries. Humans are the reservoir for Giardia, but dogs and beavers have been implicated as a zoonotic source of infection. In psittacines, the disease is commonly found in cockatiels and budgerigars. Giardiasis is a well- recognized problem in special groups including travelers, campers, male homosexuals, and persons with impaired immune states. However, Giardiasis does not appear to be an opportunistic infection in AIDS. TRANSMISSION: Only the cyst form is infectious by the oral route; trophozoites are destroyed by gastric acidity. Most infections are sporadic, resulting from cysts transmitted as a result of fecal contamination of water or food, by person-to-person contact, or by anal-oral sexual contact. After the cysts are ingested, trophozoites emerge in the duodenum and jejunum. They can cause epithelial damage, atrophy of villi, hypertrophic crypts, and extensive cellular infiltration of the lamina propria by lymphocytes, plasma cells, and neutrophils. DISEASE IN ANIMALS: Giardia infections in dogs and cats may be inapparent or produce weight loss and chronic diarrhea or steatorrhea, which can be continuous or intermittent, particularly in puppies and kittens. Calves with clinical giardiasis have been reported. Feces are usually soft, poorly formed, pale, and contain mucus. Gross intestinal lesions are seldom evident, although microscopic lesions, consisting of villous atrophy and cuboidal enterocytes, may be present. DISEASE IN MAN: Most infections are asymptomatic.
    [Show full text]
  • One Health and Neglected Tropical Diseases—Multisectoral Solutions to Endemic Challenges
    Tropical Medicine and Infectious Disease Editorial One Health and Neglected Tropical Diseases—Multisectoral Solutions to Endemic Challenges Jennifer K. Peterson 1 , Jared Bakuza 2 and Claire J. Standley 3,* 1 University Honors College, Portland State University, Portland, OR 97207, USA; [email protected] 2 Department of Biological Sciences, Dar es Salaam University College of Education, University of Dar es Salaam, Dar es Salaam, Tanzania; [email protected] 3 Center for Global Health Science and Security, Georgetown University, Washington, DC 20057, USA * Correspondence: [email protected]; Tel.: +1-202-290-0451 One Health is defined as an approach to achieve better health outcomes for humans, animals, and the environment through collaborative and interdisciplinary efforts. Increas- ingly, the One Health framework is being applied to the management, control, and even elimination of neglected tropical diseases (NTDs). NTDs are a set of debilitating and often chronic infectious diseases that, collectively, affect more than one billion people in almost 150 countries, with disproportionate impact on the extremely poor [1,2]. In this Special Is- sue, we present a diverse body of work united under the One Health ideology and a desire to mitigate the devastating effects of NTDs. The numerous diseases, methodologies, and landscapes presented highlight the interconnected and increasingly overlapping existence of humans, animals, and their pathogens. The global scope of the papers demonstrates the scale at which NTDs affect daily life. From Latin America and the Caribbean to South Asia and sub-Saharan Africa, NTDs are an ever-present reality for far too many people. The articles also highlight that NTDs are both an urban and a rural problem, and the frequency with which they cause disease Citation: Peterson, J.K.; Bakuza, J.; in animals and persist in zoonotic reservoirs exemplifies the expansive utility of the One Standley, C.J.
    [Show full text]
  • Spatial Analysis of Visceral Leishmaniasis in the Oases of the Plains of Kashi Prefecture, Xinjiang Uygur Autonomous Region
    Wang et al. Parasites & Vectors (2016) 9:148 DOI 10.1186/s13071-016-1430-8 RESEARCH Open Access Spatial analysis of visceral leishmaniasis in the oases of the plains of Kashi Prefecture, Xinjiang Uygur Autonomous Region, China Li-ying Wang1, Wei-ping Wu1*, Qing Fu1, Ya-yi Guan1, Shuai Han1, Yan-lin Niu1, Su-xiang Tong2, Israyil Osman2, Song Zhang2 and Kaisar Kaisar3 Abstract Background: Kashi Prefecture of Xinjiang is one of the most seriously affected areas with anthroponotic visceral leishmaniasis in China. A better understanding of space distribution features in this area was needed to guide strategies to eliminate visceral leishmaniasis from highly endemic areas. We performed a spatial analysis using the data collected in Bosh Klum Township in Xinjiang China. Methods: Based on the report of endemic diseases between 1990 and 2005, three villages with a high number of visceral leishmaniasis cases in Bosh Klum Township were selected. We conducted a household survey to collect the baseline data of kala-azar patients using standard case definitions. The geographical information was recorded with GIS equipment. A binomial distribution fitting test, runs test, and Scan statistical analysis were used to assess the space distribution of the study area. Results: The result of the binomial distribution fitting test showed that the distribution of visceral leishmaniasis cases in local families was inconsistent (χ2 =53.23,P < 0.01). The results of runs test showed that the distribution of leishmaniasis infected families along the channel was not random in the group of more than five infected families. The proportion of this kind of group in all infected families was 63.84 % (113 of 177).
    [Show full text]